RAC Regulatory Agency Interactions Questions and Answers 1

Question 1

A sponsor's novel drug development program is on clinical hold due to safety concerns. The sponsor has submitted a complete response to the hold issues, but the agency and sponsor agree that the path forward is unclear. Which type of formal meeting with the FDA is most appropriate to request to resolve the impasse?

Accepted Answer

Type A Meeting

Answer

A Type A meeting is specifically designed for situations that are delaying the overall product development, such as resolving a clinical hold or addressing a dispute where the development program is stalled. Type B meetings are for pre-defined milestones (e.g., pre-NDA), and Type C meetings are for any other topic not covered by Type A or B. A Pre-IND meeting would have occurred before the IND was filed and the clinical hold was placed.

Question 2

When preparing a briefing package for a Pre-Submission (Q-Sub) meeting with the FDA for a new medical device, which of the following is the MOST critical component to include?

Accepted Answer

Specific, forward-looking questions for the agency on which feedback is sought.

Answer

The primary purpose of a Q-Submission is to obtain feedback from the agency to guide product development and submission preparation. Therefore, including clear, specific, and well-reasoned questions is the most critical component, as these questions will frame the entire discussion and the feedback provided by the FDA. The other elements, while potentially part of the overall package, are secondary to the core goal of getting answers to specific regulatory, technical, or clinical questions.

Question 3

A pharmaceutical manufacturer receives an FDA Form 483 with three inspectional observations at the close-out of a GMP inspection. What is the most critical immediate action for the company?

Accepted Answer

Submit a comprehensive written response within 15 business days outlining corrective and preventive actions (CAPAs).

Answer

The FDA expects a formal written response to a Form 483 within 15 business days. A timely and thorough response that acknowledges the observations and details the company's CAPA plan is crucial. This demonstrates a commitment to compliance and can help prevent the escalation of regulatory action, such as the issuance of a Warning Letter.

Question 4

A company is developing a novel medicinal product in Europe and seeks guidance from the European Medicines Agency (EMA) on its proposed clinical development strategy. Which formal procedure should the company utilize for this purpose?

Accepted Answer

Scientific Advice

Answer

Scientific Advice is the specific procedure offered by the EMA for developers to get non-binding guidance on the appropriate tests and studies required for the development of a medicine. This process helps ensure that the development plan aligns with regulatory expectations before major resources are committed. The other options are procedures for obtaining marketing authorization, not for seeking developmental guidance.

Question 5

Following a formal meeting with the FDA, the sponsor receives the agency's official meeting minutes and identifies a significant discrepancy regarding a key agreement on the statistical analysis plan. What is the most appropriate action for the sponsor?

Accepted Answer

Formally contact the FDA within the specified timeframe to request a clarification or correction to the minutes.

Answer

Regulatory agencies have established processes that allow sponsors to review and provide comments or request clarifications on official meeting minutes, typically within a specific timeframe. This is the correct and necessary step to ensure the official record is accurate and reflects a mutual understanding. Ignoring the discrepancy or accepting an incorrect record can lead to significant regulatory risk later in development.

(RAC) Regulatory Affairs Certification Practice Test

(RAC) Regulatory Affairs Certification Practice Test

RAC Regulatory Agency Interactions Questions and Answers 1